TScan TherapeuticsNASDAQ: TCRX

WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of three abstracts for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6 – 10 in Houston, TX and virtually.

WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.51 per share a year ago.

Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors

RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning

TScan Therapeutics, Inc. (TCRX) reported a quarterly loss of $0.32 per share, which was higher than the expected loss of $0.25 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.93 per share reported in the same quarter last year.

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.78 per share a year ago.

TScan Therapeutics, Inc. (TCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Prevention relapse data from phase 1 study, using TSC-100/TSC-101 for HLA A*02:01 positive AML, MDS, and ALL patients, is expected to be released in 2024. Results from T-Plex [multiple TCR-Ts] targeting patients' solid tumors in phase 1 study are expected to be released in 2024. Amgen's multi-year collaboration deal brought in an upfront $30 million payment, $500 million possible milestone payments, and tiered royalties; First targeting Crohn's Disease and possibly later Ulcerative Colitis.